Indirect hyperbilirubinemia because of eltrombopag in two cases after autologous hematopoetic stem cell transplantation.
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
received:
31
01
2022
accepted:
01
08
2022
medline:
1
1
2023
pubmed:
1
1
2023
entrez:
22
2
2024
Statut:
ppublish
Résumé
The oral thrombopoietin receptor agonist eltrombopag has some side effects. One of them is related to bilirubin metabolism. Two patients with neuroblastoma in remission underwent stem cell transplantation with the Busulfan-melphalan regimen. Eltrombopag was started because of platelet engraftment failure. Indirect hyperbilirubinemia was detected after eltrombopag treatment. Laboratory and radiological investigations were all normal. The drugs and their side effects they used were examined. After eltombopag cutting, bilirubin levels of them returned to normal. These cases are presented to emphasize that eltrombopag can cause liver toxicity with hypertransaminesemia and hyperbilirubinemia. Drug side effects should be considered in the differential diagnosis of the patients. The significance of this case is that testing for serum aminotransferase and bilirubin levels should be monitored before and after eltrombopag use.
Identifiants
pubmed: 38384093
doi: 10.4103/jcrt.jcrt_262_22
pii: 01363817-202319002-00092
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S970-S972Informations de copyright
Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.
Références
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study. Blood 2017:130;2527–36.
Highlights of prescribing informatıon 2020 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf.
Kim TO, Despotovic J, Lambert MP Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2018:2;454–61.
Cheng THT, Tsui TKC, Kwok JSS, Lit LCW, Wong EYL, Kam RKT, et al. Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy. Clin Chem Lab Med 2020:58;1713–23.
Cardamone D, Milone MC, Glaser L, Frey NV, Kricka LJ Eltrombopag and serum of a different hue. Arch Pathol Lab Med 2013:137;1175.
Gounden V, Zhao Z Eltrombopag interference in routine chemistry testing. Ann Clin Biochem 2016:53;611–4.
Maddrey, WC, Cheng G, Khelif A, Wroblewski SL, Brainsky A Evaluation of hepatobiliary parameters during eltrombopag treatment in patients with chronic ımmune thrombocytopenic purpura. Blood 2009:114;2410.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011:377;393–402.
Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): A randomised, multicentre, placebo-controlled trial. Lancet 2015:386;1649–58.
Burness CB, Keating GM, Garnock-Jones KP Eltrombopag: A review in paediatric chronic ımmune thrombocytopenia. Drugs 2016:76;869–78.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009:373;641–8.
Moulis G, Bagheri H, Sailler L, Jonville-Bera AP, Weber E, Guy C, et al. Are adverse drug reaction patterns different between romiplostim and eltrombopag?2009–2013 French PharmacoVigilance assessment. Eur J Intern Med 2014:25;777–80.